日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program

舒尼替尼联合 FOLFIRI 方案与单纯 FOLFIRI 方案治疗化疗难治性晚期胃或下段食管腺癌患者:一项随机、安慰剂对照的 II 期 AIO 试验,并采用血清生物标志物方案

Moehler, Markus; Gepfner-Tuma, Irina; Maderer, Annett; Thuss-Patience, Peter C; Ruessel, Joern; Hegewisch-Becker, Susanna; Wilke, Hansjochen; Al-Batran, Salah-Eddin; Rafiyan, Mohammad-Reza; Weißinger, Florian; Schmoll, Hans-Joachim; Kullmann, Frank; von Weikersthal, Ludwig Fischer; Siveke, Jens T; Weusmann, Jens; Kanzler, Stephan; Schimanski, Carl Christoph; Otte, Melanie; Schollenberger, Lukas; Koenig, Jochem; Galle, Peter R

Safety and efficacy of weekly 5-fluorouracil/folinic acid/oxaliplatin/irinotecan in the first-line treatment of gastrointestinal cancer

每周一次的5-氟尿嘧啶/亚叶酸钙/奥沙利铂/伊立替康方案一线治疗胃肠道癌症的安全性和有效性

Peinert, Stefan; Grothe, Wilfried; Stein, Alexander; Müller, Lutz P; Ruessel, Joern; Voigt, Wieland; Schmoll, Hans-Joachim; Arnold, Dirk